Abstract |
PBT-1 ( clioquinol), is undergoing phase II clinical trials by Prana Biotechnology Ltd for the potential treatment of Alzheimer's disease. By October 2004, the company had planned phase III trials for the first half of 2005.
|
Authors | Richard Huckle |
Journal | Current opinion in investigational drugs (London, England : 2000)
(Curr Opin Investig Drugs)
Vol. 6
Issue 1
Pg. 99-107
(Jan 2005)
ISSN: 1472-4472 [Print] England |
PMID | 15675609
(Publication Type: Journal Article, Review)
|
Chemical References |
- Amyloid beta-Peptides
- Clioquinol
|
Topics |
- Alzheimer Disease
(drug therapy, metabolism)
- Amyloid beta-Peptides
(metabolism)
- Animals
- Clinical Trials as Topic
- Clioquinol
(adverse effects, pharmacokinetics, therapeutic use)
- Humans
|